DEINOVE

DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the microbial dark matter. By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance. The new therapies discovered and developed by DEINOVE (antibiotics, antifungals, antivirals and antiparasitics) target superbugs (microbes that resist to one or several antimicrobials) that cause life-threatening infections which are now spreading at high speed. This breakthrough approach gave birth to one of the World first specialized micro-biotechnology platforms and a unique collection of 10,000 rare...

Bioprocesses,biotransformation,biotechnology,metabolic engineering,genetic engineering,fermentation,antibiotics,and antimicrobials

Deinove operates in the Biotechnology research industry.

Deinove's revenue is 11m - 100m

Deinove has 11 - 50 employees.